Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
01 January 2018 Photo Charl Devenish
ISG’s Sarah Frank researches impact of historic conflicts on society
Dr Sarah Frank, postdoctoral researcher at the ISG.

History has an interesting connection with society, as we all grow up learning about our country’s history and studying it at school. However, what we learn at school is often a glorified version of events. It can sometimes be challenging for historians to come to grips with the most accurate version of a particular ‘history’. 

Dr Sarah Frank is a postdoctoral research fellow with the International Studies Group (ISG), who fell in love with history at a young age. She says, "I was very lucky to have outstanding history teachers at school who fostered my interest and curiosity." Early on, though, she experienced disappointment. "In school, there was a series of biographies of American leaders and presidents written for children. I remember feeling betrayed when I subsequently learnt that the biographies had not presented a well-balanced narrative. That is when I learnt that history could be debated and interpreted—and it is full of nuances."

Interested in conflict shaping lives

Dr Frank was particularly intrigued by the social and political history of the Second World War (WWII). She describes her interest in this way: "The Second World War looms in popular memory as much as in the historical one. I am interested in how conflict shaped people’s lives during and after the war." Being a speaker of French helped her to focus on the impact of the war on France, and having spent a few years living in West Africa, confronted with the lingering colonial past, she decided to home in on the French empire, with particular attention to colonies, captivity, and the repercussions of war experiences when soldiers returned home. Additionally, she explores the themes of decolonisation, the roots of independence movements, and the lingering ties between the former imperial powers and former colonies.

Although she grew up near Boston, Massachusetts, studied for her master's in Dublin, and has lived in far-flung places such as Guinea (while serving with the Peace Corps) and Dakar, Dr Frank says, "I have lived in a lot of places, but Bloemfontein is definitely one of my favourites!"

“I was very lucky to have outstanding
history teachers at school who
fostered my interest and curiosity.”
Dr Sarah Frank

Colonial POWs her new focus

Currently, Dr Frank is writing a book based on her PhD research, which delved into the experiences of approximately 85 000 soldiers in captivity from across the French Empire, who fought in France from 1939-1940. The Germans decided to racially separate the colonial prisoners of war (CPOWs), taking white prisoners to Germany and leaving the colonial prisoners in camps across occupied France. This created opportunities for colonial prisoners to interact with the French civilians, something which rarely occurred in the strict hierarchical colonial regime. Perhaps surprisingly, considering the racism of both the French and German regimes, Colonial prisoners fared better in captivity in France than their French counterparts did in Germany.

Dr Frank's next project will trace the return of the African soldiers who fought during the Second World War. She seeks to understand what happened to them as well as their families when they returned, and to see if their experience actually impacted the growing independence movements which arose following 
WWII.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept